24,618
Participants
Start Date
April 22, 2022
Primary Completion Date
May 22, 2022
Study Completion Date
June 1, 2022
Antibody-Drug Conjugate
"Compared the case reporting of sepsis-related toxicities among ADC and other common cancer drug therapies.~ADC:including Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin."
Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
We would like to include other common cancer drug therapies such as chemotherapy, targeted therapy, immunotherapy and so on as a comparator group.
Central South University, Changsha
Central South University
OTHER